title: The novel mTOR inhibitor CCI-779 (temsirolimus) induces antiproliferative effects through inhibition of mTOR in Bel-7402 liver cancer cells.
abstract: BACKGROUND
  Liver cancer is one of the most frequent cancers in the world. Targeted therapy of cancer with specific inhibitors is developing and has shown promising antitumor efficacy. CCI-779 (temsirolimus), a specific inhibitor of mTOR (mammalian target of rapamycin), can block the mTOR signaling pathway. Here, we systematically examined the expression of mTOR and its downstream targets in liver cancer cells and normal liver cells, then investigated inhibitory effects of CCI-779 on mTOR signaling pathway and its role in regulating liver cancer cell growth.
  
  
  METHODS
  The expression of mTOR and its downstream targets in Bel-7402 liver cancer cells and HL-7702 normal liver cells were examined by western blot. The mTOR specific inhibitor (CCI-779) was used to treat Bel-7402 cells to identify its effects on Bel-7402 cell growth and activity of mTOR signaling pathway in vitro. Cell viability tests were performed after the treatment of CCI-779. Western blot was applied to assess the changes of mTOR pathway and flow cytometry was used to analyze cell cycle of Bel-7402 cells after the treatment of CCI-779.
  
  
  RESULTS
  mTOR, p70S6K, S6, and 4EBP1 were overexpressed in Bel-7402 cells compared with HL-7702 cells. Bel-7402 cells were sensitive to CCI-779. The survival rate of the cells treated with CCI-779 over 0.312 μM was significantly different compared with that of control (P < 0.05). CCI-779 inhibited the phosphorylation of mTOR (Ser2448), p70S6K (Thr389), S6 (Ser240/244), and 4EBP1 (Thr37/46) in different grades and the expressions of p70S6K, S6, and 4EBP1. As a result, CCI-779 induced a dose-dependent decrease in cell proliferation, G1/S arrest and damage of cell shape.
  
  
  CONCLUSIONS
  Taken together, these data showed that CCI-779 can inhibit mTOR signaling and proliferation in Bel-7402 liver cancer cells in vitro. It offers a therapeutic intervention through inhibition of mTOR as a potential strategy for liver cancer.
authors.affiliation: College of Life Science, Inner Mongolia University, 010021, Hohhot, P.R. China.
authors.forename: Shuyu
authors.initials: S
authors.lastname: Li
authors.affiliation: College of Life Science, Inner Mongolia University, 010021, Hohhot, P.R. China.
authors.forename: Yan
authors.initials: Y
authors.lastname: Liang
authors.affiliation: College of Life Science, Inner Mongolia University, 010021, Hohhot, P.R. China.
authors.forename: Manlin
authors.initials: M
authors.lastname: Wu
authors.affiliation: College of Life Science, Inner Mongolia University, 010021, Hohhot, P.R. China.
authors.forename: Xiaojing
authors.initials: X
authors.lastname: Wang
authors.affiliation: College of Life Science, Inner Mongolia University, 010021, Hohhot, P.R. China.
authors.forename: Haixia
authors.initials: H
authors.lastname: Fu
authors.affiliation: College of Life Science, Inner Mongolia University, 010021, Hohhot, P.R. China.
authors.forename: Yuhao
authors.initials: Y
authors.lastname: Chen
authors.affiliation: College of Life Science, Inner Mongolia University, 010021, Hohhot, P.R. China.
authors.forename: Zhigang
authors.initials: Z
authors.lastname: Wang
keywords: CCI-779 (temsirolimus); Cell growth; Liver cancer cell; mTOR signaling
references.citation: Semin Liver Dis. 2010 Feb;30(1):87-98
references.pmid: 20175036
references.citation: Clin Cancer Res. 2003 Aug 1;9(8):2887-92
references.pmid: 12912932
references.citation: Nature. 2006 May 25;441(7092):424-30
references.pmid: 16724053
references.citation: Cancer. 2011 Nov 15;117(22):5094-102
references.pmid: 21538343
references.citation: Endocr Relat Cancer. 2001 Sep;8(3):249-58
references.pmid: 11566616
references.citation: Science. 2007 Nov 9;318(5852):977-80
references.pmid: 17991864
references.citation: Invest New Drugs. 2010 Jun;28(3):334-42
references.pmid: 19415181
references.citation: Liver Int. 2010 Jan;30(1):65-75
references.pmid: 19845851
references.citation: N Engl J Med. 2007 May 31;356(22):2271-81
references.pmid: 17538086
references.citation: Cell. 2006 Feb 10;124(3):471-84
references.pmid: 16469695
references.citation: J Gastrointest Surg. 2007 May;11(5):589-95
references.pmid: 17393258
references.citation: Oncogene. 2000 Dec 27;19(56):6680-6
references.pmid: 11426655
references.citation: Oncologist. 2007 Aug;12(8):1007-18
references.pmid: 17766661
references.citation: Ann Oncol. 2005 Apr;16(4):525-37
references.pmid: 15728109
references.citation: Gastroenterology. 2008 Dec;135(6):1972-83, 1983.e1-11
references.pmid: 18929564
references.citation: J Hepatol. 2012 Jan;56(1):176-83
references.pmid: 21835141
references.citation: Acta Pharmacol Sin. 2007 Sep;28(9):1305-15
references.pmid: 17723164
references.citation: Br J Cancer. 2006 Jan 30;94(2):195-9
references.pmid: 16404421
references.citation: Proc Natl Acad Sci U S A. 2010 Jan 5;107(1):264-9
references.pmid: 20018759
references.citation: Cancer Lett. 2010 Dec 18;299(1):22-8
references.pmid: 20727673
references.citation: J Clin Oncol. 2005 Aug 10;23(23):5314-22
references.pmid: 15955899
references.citation: CA Cancer J Clin. 2011 Mar-Apr;61(2):69-90
references.pmid: 21296855
references.citation: PLoS One. 2012;7(5):e36713
references.pmid: 22615798
references.citation: Cancer Res. 2010 Jan 1;70(1):288-98
references.pmid: 20028854
references.citation: Invest New Drugs. 2005 Aug;23(4):357-61
references.pmid: 16012795
references.citation: Oncol Rep. 2010 Apr;23(4):1167-72
references.pmid: 20204306
references.citation: J Clin Oncol. 2004 Jun 15;22(12):2336-47
references.pmid: 15136596
references.citation: Cell. 2000 Oct 13;103(2):253-62
references.pmid: 11057898
references.citation: Expert Opin Investig Drugs. 2008 Nov;17(11):1717-34
references.pmid: 18922108
references.citation: Oncogene. 2006 Oct 16;25(48):6436-46
references.pmid: 17041628
references.citation: Clin Transl Oncol. 2007 Aug;9(8):484-93
references.pmid: 17720651
references.citation: Gastroenterology. 2004 Nov;127(5 Suppl 1):S5-S16
references.pmid: 15508102
references.citation: Exp Hematol. 2011 Apr;39(4):457-472.e3
references.pmid: 21277936
references.citation: Cancer Res. 2011 Jun 15;71(12):4074-84
references.pmid: 21540234